echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Junshi Bio's Toripalimab in the Treatment of Small Cell Lung Cancer Receives FDA Orphan Drug Designation

    Junshi Bio's Toripalimab in the Treatment of Small Cell Lung Cancer Receives FDA Orphan Drug Designation

    • Last Update: 2022-05-21
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On April 13, Toripalimab, an anti-PD-1 monoclonal antibody independently developed by Junshi Bio for the treatment of small cell lung cancer (SCLC), was granted orphan drug designation by the U.


    Lung cancer is the second most common malignant tumor in the world


    Currently, Junshi Biosciences is conducting a registrational clinical study for small cell lung cancer, the JUPITER-08 study (NCT04012606), and has completed the enrollment of subjects


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.